Hypertonic Saline for MAC

Description

The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.

Conditions

Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection

Talk to us

Study Overview

On this page

Study Details

Study overview

The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.

Hypertonic Saline for Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease

Hypertonic Saline for MAC

Condition
Nontuberculous Mycobacterial Lung Disease
Intervention / Treatment

-

Contacts and Locations

New York

NYU Langone Health, New York, New York, United States, 10016

Portland

Oregon Health & Science University, Portland, Oregon, United States, 97239

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * At least 2 positive MAC sputum cultures in the last 12 months with at least one AFB positive sputum obtained within 12 weeks prior to randomization
  • * Meet American Thoracic Society (ATS)/ Infectious Disease Society of America (IDSA) 2007 pulmonary clinical disease criteria\[1\]
  • * Age 18 and older
  • * Diagnosis of Bronchiectasis and/or bronchiectatic findings evident on chest CT report
  • * Ability to provide informed consent
  • * Any patient who is unwilling or unable to provide consent or to comply with this protocol
  • * Cavitary NTM disease
  • * Patients who are currently taking or within the prior 6 months received any of the following: bedaquiline, or any component of ATS/IDSA multi-drug recommended therapy (macrolide, ethambutol, rifampin) for MAC treatment
  • * Diagnosis of HIV
  • * Diagnosis of Cystic fibrosis
  • * Active pulmonary tuberculosis, fungal, or nocardial disease requiring treatment at screening
  • * Current use of chronic systemic corticosteroids at doses of 15 mg/day for more than 3 months
  • * Prior lung or other solid organ transplant

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Oregon Health and Science University,

Study Record Dates

2025-06-30